Steve E. Krognes, Director at Denali Therapeutics Inc. (DNLI), sold 30,688 shares at $22.12 ($679K) on 2024-07-01, disclosed to the SEC on 2024-07-03.
Scheduled sale ($679k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.79 | 688 | $15K | 2.2% |
| 2 | $22.12 | 29,900 | $661K | 97.5% |
| 3 | $22.80 | 100 | $2K | 0.3% |
| Total | $22.11 avg | 30,688 | $679K | 100% |
| Filing → |
| DNLI | SELL | 2025-01-08 | $139K | — | Filing → |
| DNLI | SELL | 2025-01-03 | $608K | — | Filing → |
| DNLI | SELL | 2024-10-02 | $871K | — | Filing → |